The annual American Society of Clinical Oncology conference is over for another year. News out of the conference dominated much of the health news agenda over the past week.
On the In Vivo blog, Mary Jo Laffler reflected on how:
“…increasingly, the importance of the data being presented before packed meeting halls is being questioned. “We need to get away from things that add cost but not value,” UnitedHealthcare’s Lee Newcomer noted during a panel on health care reform.
Defining what value means, however, is a trickier subject.
Most clinical trials don’t mean much for clinical practice, Ralph Meyer of Queen’s University asserted at the plenary on randomized clinical trials. With all the controls and standardization, they represent the ideal – not real world practice.
…
In a talk called “Raising the Bar for Efficacy In Cancer Therapeutics,” Alberto Sobrero, Head of the Medical Oncology Unit at Italy’s Ospedale San Martino, took on whether or not those trials produce clinically meaningful data, or just go after statistical significance.
…
Unlike in the past, the skepticism of therapeutic value outlined in posters and abstracts isn’t limited to the back corridors or the marginal sessions on clinical trial design and practice issues — it’s coming from the podium at scientific sessions.
…
It’s great to see researchers and industry execs coming out of the convention with excitement about promising new pathways and the potential for combinations. But they should also start thinking harder about raising the bar. Otherwise climate change (of a reimbursement and/or regulatory nature) could spark a cool down in one of the hottest therapeutic areas of the industry.”
Opinions on other issues in news, journals, PR, advertising, marketing
A lot of interesting workshops are happening now at the #NBCCSummit! @garyschwitzer, the publisher of @HealthNewsRevu, is discussing new cancer research news. #BeBold
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Comments are closed.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like